CALR Mutation–Directed Agents and Targeted Therapies Represent Key Research Avenue in MPN Management
Key claim: The phase 3 SENTRY trial met its first co-primary endpoint showing statistically significant spleen volume reduction with selinexor plus ruxolitinib in first-line myelofibrosis, while CALR-directed therapies and combination regimens represent key emerging research avenues in MPN management.
Abstract
Karyopharm’s phase 3 SENTRY trial met first co-primary endpoint in March 2026, demonstrating statistically significant improvement in spleen volume reduction with selinexor plus rituximab in first-line myelofibrosis. Expert commentary discusses ongoing trials including MANIFEST-3 (pelabresib plus ruxolitinib), IMpactMF (imetelstat), and CALR-specific monoclonal antibody INCA033989 studies.
Why this matters
For symptom management, splenomegaly remains a primary driver of early satiety, abdominal discomfort, and cytopenias, and the SENTRY readout strengthens the case for ruxolitinib-combination regimens as a spleen-directed option beyond monotherapy. The broader synthesis (CALR-directed agents, BET inhibitors, XPO1 combinations) signals an expanding menu of spleen-reducing therapies that may translate into better symptom control for patients with inadequate response to single-agent JAK inhibition.